Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.53 +2.02%
Revenue Growth %: -33.6%
Financial Fact:
NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:: -0.07
Today's EPS Names:
GBFH, JMKE, FDX, More
Revenue Growth %: -33.6%
Financial Fact:
NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:: -0.07
Today's EPS Names:
GBFH, JMKE, FDX, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.05), versus ($0.07) reported last year.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Orion Marine Group (ORN) Tops Q3 EPS by 3c ; Offers Guidance
- NOV Inc (NOV) Reports In-Line Q3 EPS
- Deutsche Bank Aktiengesellschaft (DB) Tops Q3 EPS by 2c; offers outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
